Growth Metrics

10x Genomics (TXG) EBIAT (2018 - 2025)

Historic EBIAT for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$16.3 million.

  • 10x Genomics' EBIAT rose 6685.16% to -$16.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$43.5 million, marking a year-over-year increase of 7615.69%. This contributed to the annual value of -$43.5 million for FY2025, which is 7615.69% up from last year.
  • As of Q4 2025, 10x Genomics' EBIAT stood at -$16.3 million, which was up 6685.16% from -$27.5 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' EBIAT registered a high of $34.5 million during Q2 2025, and its lowest value of -$93.0 million during Q3 2023.
  • In the last 5 years, 10x Genomics' EBIAT had a median value of -$36.8 million in 2024 and averaged -$35.3 million.
  • As far as peak fluctuations go, 10x Genomics' EBIAT plummeted by 48322.48% in 2022, and later surged by 19113.65% in 2025.
  • 10x Genomics' EBIAT (Quarter) stood at -$18.4 million in 2021, then increased by 6.69% to -$17.2 million in 2022, then plummeted by 184.36% to -$49.0 million in 2023, then dropped by 0.16% to -$49.0 million in 2024, then soared by 66.85% to -$16.3 million in 2025.
  • Its last three reported values are -$16.3 million in Q4 2025, -$27.5 million for Q3 2025, and $34.5 million during Q2 2025.